Sternbach G L, Schroeder J S, Eliastam M, Beier-Scott L
Clin Cardiol. 1986 Apr;9(4):145-9. doi: 10.1002/clc.4960090403.
To determine the effects of diltiazem hydrochloride on patients with paroxysmal supraventricular tachycardia, we administered intravenous diltiazem, 0.25 mg/kg to patients who presented to the Stanford Medical Center Emergency Department with this rhythm. Blood pressure was recorded prior to administration, and monitored for 20 min thereafter. Six of the ten patients converted to sinus rhythm a mean of 7.75 min (+/- 4.4) after drug administration. The remaining four experienced slowing of heart rates from a mean of 177 to 166 beats/min. Systolic blood pressure fell a mean of 12.4 mmHg during treatment, but returned to pretreatment level or higher within 20 min following diltiazem administration. This mean degree of blood pressure reduction compares favorably with effects produced by intravenous verapamil under comparable circumstances. Intravenous diltiazem appears to be a safe and effective drug for the conversion of paroxysmal supraventricular tachycardia.
为确定盐酸地尔硫䓬对阵发性室上性心动过速患者的疗效，我们对前往斯坦福医学中心急诊科就诊且有该心律失常的患者静脉注射了0.25mg/kg的地尔硫䓬。给药前记录血压，并在给药后监测20分钟。10名患者中有6名在给药后平均7.75分钟（±4.4）转为窦性心律。其余4名患者的心率从平均177次/分钟降至166次/分钟。治疗期间收缩压平均下降12.4mmHg，但在静脉注射地尔硫䓬后20分钟内恢复到治疗前水平或更高。这种平均血压降低程度与在类似情况下静脉注射维拉帕米产生的效果相比具有优势。静脉注射地尔硫䓬似乎是一种安全有效的用于阵发性室上性心动过速转复的药物。
